Literature DB >> 20104499

Impact of pretransplant infections on clinical outcomes of liver transplant recipients.

Hsin-Yun Sun1, Thomas V Cacciarelli, Nina Singh.   

Abstract

Whether pretransplant nonviral infections influence outcomes after transplantation in liver transplant recipients in the current era is not well defined. One hundred consecutive patients undergoing liver transplantation in 2005-2008 were studied. Demographics, posttransplant clinical events, and mortality were compared between recipients with and without infections within 12 months before transplantation. In all, 32% of the patients (32/100) developed 45 episodes of pretransplant infections, which included spontaneous bacterial peritonitis (35.6%), bloodstream infections (28.9%), cellulitis (13.3%), pneumonia (8.9%), urinary tract infections (6.7%), and other infections (6.7%). Compared with 68 recipients without pretransplant infections, those with infections had a higher Model for End-Stage Liver Disease score and a lower likelihood of transplantation from home and required longer and more frequent hospital care before and after transplantation (P < 0.05). Mortality at 90 (9.4% versus 2.9%) and 180 days (15.6% versus 10.3%) post-transplant did not differ significantly between recipients with and without pretransplant infections (P = not significant). A higher Model for End-Stage Liver Disease score (P < 0.05) and posttransplant infections (P < 0.05 and P < 0.001), but not pretransplant infections, were associated with posttransplant mortality at 90 and 180 days. In conclusion, pretransplant infections that have been adequately treated do not pose a significant risk for poor outcomes, including posttransplant mortality.

Entities:  

Mesh:

Year:  2010        PMID: 20104499     DOI: 10.1002/lt.21982

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  7 in total

1.  Antibiotic pretreatment alleviates liver transplant damage in mice and humans.

Authors:  Kojiro Nakamura; Shoichi Kageyama; Takahiro Ito; Hirofumi Hirao; Kentaro Kadono; Antony Aziz; Kenneth J Dery; Matthew J Everly; Kojiro Taura; Shinji Uemoto; Douglas G Farmer; Fady M Kaldas; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  J Clin Invest       Date:  2019-07-22       Impact factor: 14.808

2.  Pretransplant fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae and infection after liver transplant, France.

Authors:  Frédéric Bert; Béatrice Larroque; Catherine Paugam-Burtz; Federica Dondero; François Durand; Estelle Marcon; Jacques Belghiti; Richard Moreau; Marie-Hélène Nicolas-Chanoine
Journal:  Emerg Infect Dis       Date:  2012-06       Impact factor: 6.883

3.  Impacts of pretransplant infections on clinical outcomes of patients with acute-on-chronic liver failure who received living-donor liver transplantation.

Authors:  Kuo-Hua Lin; Jien-Wei Liu; Chao-Long Chen; Shih-Hor Wang; Chih-Che Lin; Yueh-Wei Liu; Chee-Chien Yong; Ting-Lung Lin; Wei-Feng Li; Tsung-Hui Hu; Chih-Chi Wang
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

4.  Spontaneous bacterial peritonitis prevalence in pre-transplant patients and its effect on survival and graft loss post-transplant.

Authors:  Neeral L Shah; Nicolas M Intagliata; Zachary H Henry; Curtis K Argo; Patrick G Northup
Journal:  World J Hepatol       Date:  2016-12-28

Review 5.  Management of bacterial infection in the liver transplant candidate.

Authors:  Alberto Ferrarese; Alberto Zanetto; Chiara Becchetti; Salvatore Stefano Sciarrone; Sarah Shalaby; Giacomo Germani; Martina Gambato; Francesco Paolo Russo; Patrizia Burra; Marco Senzolo
Journal:  World J Hepatol       Date:  2018-02-27

6.  Impact of pre-transplant infection management on the outcome of living-donor liver transplantation in Egypt.

Authors:  Ahmed Mohamed Saleh; Essam Ali Hassan; Ahmed Ali Gomaa; Tamer Mahmoud El Baz; Mohamed El-Abgeegy; Mohamed Ismail Seleem; Yousry Esam-Eldin Abo-Amer; Heba Fadl Elsergany; Eman Ibrahim El-Desoki Mahmoud; Sherief Abd-Elsalam
Journal:  Infect Drug Resist       Date:  2019-07-24       Impact factor: 4.003

Review 7.  Management of bacterial and fungal infections in end stage liver disease and liver transplantation: Current options and future directions.

Authors:  Elda Righi
Journal:  World J Gastroenterol       Date:  2018-10-14       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.